• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    Feb 24, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Principles for designing future regimens for multidrug-resistant tuberculosis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Brigden et al-2013-Principles ...
    Size:
    801.1Kb
    Format:
    PDF
    Download
    Authors
    Brigden, G
    Nyang'wa, B-T
    du Cros, P
    Varaine, F
    Hughes, J
    Rich, M
    Horsburgh, C R
    Mitnick, C D
    Nuermberger, E
    McIlleron, H
    Phillips, Patrick P J
    Balasegaram, M
    Show allShow less
    Issue Date
    2014-01-01
    
    Metadata
    Show full item record
    Journal
    Bulletin of the World Health Organization
    Abstract
    Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex, ineffective, poorly tolerated and expensive. For the first time in over 50 years, new drugs have been developed specifically to treat tuberculosis, with bedaquiline and potentially delamanid expected to be available soon for treatment of MDR cases. However, if the new drugs are merely added to the current treatment regimen, the new regimen will be at least as lengthy, cumbersome and toxic as the existing one. There is an urgent need for strategy and evidence on how to maximize the potential of the new drugs to improve outcomes and shorten treatment. We devised eight key principles for designing future treatment regimens to ensure that, once they are proven safe in clinical trials, they will be clinically effective and programmatically practicable. Regimens should contain at least one new class of drug; be broadly applicable for use against MDR and extensively drug-resistant Mycobacterium tuberculosis complex strains; contain three to five effective drugs, each from a different drug class; be delivered orally; have a simple dosing schedule; have a good side-effect profile that allows limited monitoring; last a maximum of 6 months; and have minimal interaction with antiretrovirals. Following these principles will maximize the potential of new compounds and help to overcome the clinical and programmatic disadvantages and scale-up constraints that plague the current regimen.
    Publisher
    World Health Organization
    URI
    http://hdl.handle.net/10144/311647
    DOI
    10.2471/BLT.13.122028
    PubMed ID
    24391302
    Language
    en
    ISSN
    1564-0604
    ae974a485f413a2113503eed53cd6c53
    10.2471/BLT.13.122028
    Scopus Count
    Collections
    TB

    entitlement

    Related articles

    • Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    • Authors: Wirth D, Dass R, Hettle R
    • Issue date: 2017 Mar 8
    • Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    • Authors: Mohr E, Ferlazzo G, Hewison C, De Azevedo V, Isaakidis P
    • Issue date: 2019 May
    • Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    • Authors: Szumowski JD, Lynch JB
    • Issue date: 2015
    • Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    • Authors: Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J
    • Issue date: 2018 Jul
    • Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    • Authors: Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S
    • Issue date: 2017 Feb 7
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.